CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 260 enrolled
Drug / intervention
Kidney transplant biopsyprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03206801
NCT03206801Phase 3Completed
CompareCT.gov

A Randomized Controlled Trial of Urine CXCL10 Chemokine Monitoring Post-renal Transplant

University of Manitoba·interventional·Posted Jul 2, 2017·Updated May 5, 2026

In Brief

A Phase 3 clinical trial evaluating Kidney transplant biopsy for Kidney Transplant; Complications and Rejection of Renal Transplant. Completed, enrolled 260 participants across 9 sites in 2 countries.

Detailed Summary

This is a Phase II-III multi-center prospective randomized controlled clinical trial of incident adult renal transplant patients. The primary objective of this study is to determine if the early treatment of rejection, as detected by urinary CXCL10, will improve renal allograft outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplant; Complications, Rejection of Renal Transplant
CountriesAustralia, Canada
CollaboratorsCanadian Institutes of Health Research (CIHR), Canadian National Transplant Research Program

Timeline

Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedJul 2, 2017
Enrollment StartApr 3, 2018
Primary CompletionJun 6, 2025
Study CompletionSep 26, 2025
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 9 years ago

Interventions

Kidney transplant biopsyprocedure

Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.